The growing desire for point-of-care diagnostic testing will have an impact on the industry’s growth. Rapid findings from point-of-care testing are becoming increasingly important for timely diagnosis and treatment in urgent care centres, emergency rooms, and ambulances. The increased need for quick diagnosis and treatment, which helps to improve patient outcomes while catering to a variety of ailments or infectious diseases, has paved the way for new technologies, driving market share even further.
Limited understanding of infection control and prevention, as well as personal health and hygiene, particularly in developing countries, may constitute a significant hurdle to the need for infectious disease diagnostics. Many hospitals are struggling with inadequate infrastructure, such as poor water sanitation and hygiene facilities. Other issues restricting market expansion include a lack of training among healthcare workers for infection control in healthcare settings, personnel shortages, and inadequate compliance of hospital and patient staff with cleanliness standards.
Infectious illness diagnostics reagents, kits, and consumables market share was more than USD 12 billion in 2022. This is due to the widespread availability of reagents, kits, and consumables for detecting a variety of infectious illnesses using specific pathogens and diagnostic tests. The increasing use of RT-PCR in detecting RNA viruses such as influenza, SARS-CoV-2, and hepatitis C will further contribute to the market landscape.
Pathogens that cause respiratory infections have increased significantly in recent years, including bacteria, viruses, fungi, and parasites. Chest X-rays, such as CT scans, physical exams, and laboratory tests, such as PCR testing of respiratory secretions and blood, are increasingly being used to diagnose and treat respiratory infections. The increased importance of these tests for diagnosing the source of respiratory infections and recommending the best course of action will have an impact on the industrial landscape.
The segmentation coverage of the study is provided below.
Infectious Disease Diagnostics Market based on Product:
- Assays & Reagents
- Hepatitis
- Human Immunodeficiency Virus
- Influenza
- Others
- Instruments
- Hepatitis
- Human Immunodeficiency Virus
- Influenza
- Others
- Software
- Hepatitis
- Human Immunodeficiency Virus
- Influenza
- Others
Infectious Disease Diagnostics Market based on Disease Type:
- Hepatitis
- Human Immunodeficiency Virus
- Influenza
- Others
Infectious Disease Diagnostics Market based on Technology:
- Immunodiagnostics
- Clinical Microbiology
- Polymerase Chain Reaction
- Next Generation Sequencing
- Others
Infectious Disease Diagnostics Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The study’s goal is to examine important market dynamics such as drivers, opportunities, constraints, challenges, and key player strategies. The competitive landscape of the infectious disease diagnostics market to analyse market players on various parameters within the broad categories of business and product strategy. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The market size was estimated using both top-down and bottom-up methods. The market split and data triangulation were used to estimate the market size of segments and subsegments.
Various sources from both the supply and demand sides were interviewed throughout the main research phase to collect qualitative and quantitative information for this study. Primary sources included industry experts from the core and associated industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organisations involved in all sectors of the value chain of this business. To acquire and verify crucial qualitative and quantitative information, as well as analyse prospects, in-depth interviews were performed with a variety of primary respondents, including significant industry participants, subject-matter experts, C-level executives of key market companies, and industry consultants.
Various secondary sources, such as annual reports, press releases, and investor presentations of companies, white papers, certified publications, articles by recognised authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were used to identify and collect information for this study during the secondary research process.
Following the use of the above-mentioned procedure to determine the overall market size, the complete market was divided into many segments and subsegments. Data triangulation and market breakdown processes were used whenever applicable to complete the whole market engineering process and arrive at the correct numbers for all segments and subsegments. The information was triangulated by examining numerous elements and trends on both the demand and supply sides.
Infectious disease diagnostics refers to the techniques and products used by healthcare professionals to detect and diagnose disease-causing pathogens in human samples such as serum, blood, urine, throat swab, and stool, among others.
The major players in infectious disease diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), bioMérieux (France), Siemens Healthineers AG (Germany), and Danaher (US). These players lead the market because of their extensive product portfolios and wide geographic presence.
- This report illustrates the most vital attributes of the Infectious Disease Diagnostics Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Infectious Disease Diagnostics Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Infectious Disease Diagnostics Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Infectious Disease Diagnostics Market.
List of Tables
TABLE 1. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR ASSAYS & REAGENTS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR SOFTWARE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 6. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR HEPATITIS, 2021-2030 (USD BILLION)
TABLE 7. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR HUMAN IMMUNODEFICIENCY VIRUS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 11. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR IMMUNODIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR CLINICAL MICROBIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR POLYMERASE CHAIN REACTION, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR NEXT GENERATION SEQUENCING, 2021-2030 (USD BILLION)
TABLE 15. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 20. U.S INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. U.S INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 23. CANADA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 24. CANADA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 25. CANADA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 26. MEXICO INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. MEXICO INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 28. MEXICO INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 29. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 30. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 33. GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 34. GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 35. GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 36. U.K INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 37. U.K INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 38. U.K INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 39. FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 40. FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 41. FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 42. ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 43. ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 44. ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 45. SPAIN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. SPAIN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 47. SPAIN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 48. ROE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ROE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 50. ROE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 55. CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 57. CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 58. INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 59. INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 60. INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 61. JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 62. JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 63. JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 82. UAE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 83. UAE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 84. UAE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 88. AMGEN, INC. : FINANCIALS
TABLE 89. AMGEN, INC. : PRODUCTS & SERVICES
TABLE 90. AMGEN, INC. : RECENT DEVELOPMENTS
TABLE 91. ASTRAZENECA, PLC: FINANCIALS
TABLE 92. ASTRAZENECA, PLC: PRODUCTS & SERVICES
TABLE 93. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
TABLE 94. BAYER AG: FINANCIALS
TABLE 95. BAYER AG: PRODUCTS & SERVICES
TABLE 96. BAYER AG: RECENT DEVELOPMENTS
TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 100. ELI LILY AND COMPANY: FINANCIALS
TABLE 101. ELI LILY AND COMPANY: PRODUCTS & SERVICES
TABLE 102. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
TABLE 103. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
TABLE 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
TABLE 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
TABLE 106. PFIZER, INC. : FINANCIALS
TABLE 107. PFIZER, INC. : PRODUCTS & SERVICES
TABLE 108. PFIZER, INC. : DEVELOPMENTS
TABLE 109. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
TABLE 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
TABLE 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
TABLE 112. MERCK KGAA: FINANCIALS
TABLE 113. MERCK KGAA: PRODUCTS & SERVICES
TABLE 114. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 115. NOVARTIS AG: FINANCIALS
TABLE 116. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 117. NOVARTIS AG: RECENT DEVELOPMENTS
